Global HIV Integrase Strand Transfer Inhibitors (INSTI) Market Growth (Status and Outlook) 2025-2031

According to this study, the global HIV Integrase Strand Transfer Inhibitors (INSTI) market size will reach US$ million by 2031.

United States market for HIV Integrase Strand Transfer Inhibitors (INSTI) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for HIV Integrase Strand Transfer Inhibitors (INSTI) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for HIV Integrase Strand Transfer Inhibitors (INSTI) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key HIV Integrase Strand Transfer Inhibitors (INSTI) players cover Adcock Ingram Limited, Affine Formulations Limited, Aurobindo Pharma, Biocon Limited, Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “HIV Integrase Strand Transfer Inhibitors (INSTI) Industry Forecast” looks at past sales and reviews total world HIV Integrase Strand Transfer Inhibitors (INSTI) sales in 2024, providing a comprehensive analysis by region and market sector of projected HIV Integrase Strand Transfer Inhibitors (INSTI) sales for 2025 through 2031. With HIV Integrase Strand Transfer Inhibitors (INSTI) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV Integrase Strand Transfer Inhibitors (INSTI) industry.

This Insight Report provides a comprehensive analysis of the global HIV Integrase Strand Transfer Inhibitors (INSTI) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on HIV Integrase Strand Transfer Inhibitors (INSTI) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global HIV Integrase Strand Transfer Inhibitors (INSTI) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Integrase Strand Transfer Inhibitors (INSTI) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Integrase Strand Transfer Inhibitors (INSTI).

This report presents a comprehensive overview, market shares, and growth opportunities of HIV Integrase Strand Transfer Inhibitors (INSTI) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Raltegravir
Elvitegravir Combination Drugs
Dolutegravir and Its Combination Drug
Bictegravir Combination Drug
Cabotegravir
Others

Segmentation by Application:
Hospital
Clinic
Drug Center
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Adcock Ingram Limited
Affine Formulations Limited
Aurobindo Pharma
Biocon Limited
Bristol-Myers Squibb
Cipla
Emcure Pharmaceuticals
Flamingo Pharmaceuticals Limited
Gilead Sciences
Hetero Drugs
IPCA Laboratories
Janssen Pharmaceutica (Johnson & Johnson)
LAURUS Labs
Medisist Pharma
Merck
Mylan
Ranbaxy Pharmaceuticals
Shanghai Desano Pharmaceuticals
ViiV Healthcare (GSK)

Please note: The report will take approximately 2 business days to prepare and deliver. Show more